Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/1/2006 First Published: 1/26/2003


1.		Phase III Randomized Study of Methylprednisolone With or Without Daclizumab in Patients With Acute Graft-Versus-Host Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI, Pharmaceutical / Industry				DFCI-99279 RPCI-DS-0218, ROCHE-RPCI-DS-0218, NCT00053976

Last Modified: 10/17/2003


2.		Phase Ib/II Trial of Humanized Anti-Tac Monoclonal Antibody and Interleukin-2 for Leukemia and Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				BIDMC-92020534 NEDH-92020534, BIDMC-FDR001054, NCI-H95-0732, NCT00002681

Last Modified: 11/14/2007


3.		Phase I/II Pilot Study of Anti-Tac Antibody Immunotherapy in Adults with Tac-Positive T-Cell Leukemia/Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				NCI-83-C-23 NCI-T84-0153N

Last Modified: 8/1/1989


4.		Phase I/II Preliminary Feasibility Study of Immunotherapy with Pseudomonas Conjugated Anti-Tac Antibody for Adult T-Cell Leukemia/Lymphoma (Summary Last Modified 08/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-85-C-91 NCI-T85-0147N, T85-0147

Last Modified: 6/1/1997


5.		Phase II Study of 90Y-Humanized Anti-Tac for Tac-Expressing Post-Thymic T-Cell Malignancies Other Than Adult T-Cell Leukemia (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCI-94-C-0068D

Last Modified: 1/1/2002 First Published: 10/1/2000


6.		Phase II Study of Nonmyeloablative Conditioning Regimen Followed by HLA Matched Sibling Donor Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancies (Summary Last Modified 01/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 18				Other				MSGCC-0012 NCI-V00-1624, NCT00006350

Last Modified: 5/1/2000


7.		Phase II Study of Yttrium-90-Labeled Humanized Anti-Tac MOAB in Patients with Tac-Expressing Adult T-Cell Leukemia/Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-93-C-0066F

Last Modified: 12/21/2007


8.		Phase I Study of Yttrium 90 Labeled Monoclonal Antibody Anti-Tac in Patients With Tac Expressing Cutaneous T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-90-C-43A

Last Modified: 6/1/1999


9.		Phase I Study of Single Intravenous Doses of Humanized Anti-Tac (Ro 24-7375) in Patients with Tac-Bearing Malignancies (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-92-C-0046 NCI-T91-0276N, T91-0276

Last Modified: 12/9/2008 First Published: 2/27/2008


10.		Pilot Study of Regulatory T-Cell Inhibition With Daclizumab During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly Diagnosed Glioblastoma Multiforme and Therapeutic Temozolomide-Induced Lymphopenia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Diagnostic, Treatment				Closed				18 and over				NCI				DUMC-PRO00000581 Pro00000581, SPORE Project 3, NCT00626483

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute